Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs Humira for Uveitis
September 12, 2016
- Kaketsuken’s Business Transfer Necessary: MHLW Official
September 9, 2016
- MHLW Reports Partial Modifications of Approval for 3 Drugs Including Polidocasklerol to Advisory Panel
September 9, 2016
- MHLW Panel Backs BI’s Triple Combo After 3rd Try
September 9, 2016
- NIBIOHN Strengthens Collaboration with Drug Makers to Promote Development of Japan-Originated Drugs
September 8, 2016
- MHLW Re-Stresses Caution over Use of EGFR TKIs in Opdivo-Treated Patients
September 7, 2016
- Barcode Labeling Increasing in Anticipation of Mandatory Use in 2021: MHLW Survey
September 6, 2016
- 6 National Centers Log Generic Use Rate of Average 73.8% in FY2015
September 6, 2016
- MHLW Issues Notification on Partial Revision of Rules for New Barcode Labeling to Be Required from April 2021
September 6, 2016
- PMDA to Host Int’l Seminars in 2017 under Asian Training Center Initiative
September 5, 2016
- G7 Health Ministers to Discuss AMR Measures at Upcoming Kobe Confab
September 5, 2016
- METI Seeks 7.2 Bil. Yen for Drug Discovery, 3.5 Bil. for Regenerative Medicine
September 2, 2016
- Panel OKs Iridosteresis, 7 Other Illnesses as Designated Intractable Diseases
September 1, 2016
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- “Untreated” Erased from Viekirax’s Add’l Indication: Sept. 9 Panel Meeting
August 31, 2016
- Lilly Drops Listing of Taltz amid Pricing Fuss, Wants to Deliver Drug without Restrictions
August 31, 2016
- MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November
August 30, 2016
- MHLW Unveils FY2017 Budget Request, 105.8 Bil. Yen Sought for Healthcare Innovation
August 29, 2016
- MHLW Requests Extension of R&D Tax Credit for “High-Level Investment”
August 29, 2016
- MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs
August 29, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…